| 2.67 -0.08 (-2.91%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Biofrontera AG is a biopharmaceutical firm dedicated to the creation and marketing of pharmaceutical solutions. The company primarily targets dermatological ailments and conditions predominantly arising from sun exposure and its harmful effects on the skin. Central to its product offerings is Ameluz, a prescribed drug for addressing both localized lesions and broader areas affected by actinic keratosis. Biofrontera also supplies the BF-RhodoLED lamp, a device utilized in photodynamic therapy for the exact same lesion-directed and field-directed treatment of actinic keratosis. Additionally, its portfolio includes Belixos, an over-the-counter collection of skincare cosmetic products. Looking ahead, Biofrontera is progressing the development of Ameluz for treating field cancerization and nodular basal cell carcinoma. Its wider product range encompasses Xepi, a prescription antibiotic cream for impetigo, and Aktipak, a generic medication for acne. The company's products are available primarily in the United States, Europe, and Israel. Biofrontera AG also maintains a collaborative and partnership agreement with Maruho Co., Ltd. Established in 1997, the company's main office is located in Leverkusen, Germany.
Thu, 24 Apr 2025
BFRA Stock Price, News & Analysis - Stock Titan
Thu, 28 Oct 2021
BFRI IPO News - Dermatological drug spinoff Biofrontera Inc. prices IPO at $5, the low end of the range - renaissancecapital.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|